Abstract
Clinical and experimental evidence indicates that estrogens are involved in the control of hepatocyte proliferation both in normal and in neoplastic conditions. Thirty-two cirrhotic patients with unresectable or otherwise untreatable hepatocellular carcinoma were allocated to receive either tamoxifen (30 mg/day) or no treatment. The patients in the two groups were matched for age, male/female ratio, Child-Pugh class, approximate tumor volume (US and CT scan), and etiology of the underlying cirrhosis. Survival of the tamoxifen-treated patients (life-table, Wilcoxon-Breslow) was significantly prolonged (P=0.0038), with 35% (vs 0%) survival at 12 months. No difference was observed between males and females or between alcoholic and nonalcoholic cirrhosis. In 40% of tamoxifen-treated patients, the levels of α-fetoprotein declined. In conclusion, the antiestrogen tamoxifen appears to be effective in the palliative treatment of hepatocellular carcinoma. An initial decline in α-fetoprotein levels may represent an early favorable prognostic sign.
References
Aldercrutz H, Tenhunen R: Some aspects of the interaction between natural and synthetic female sex hormones and the liver. Am J Med 49:630–648, 1970
Stauffer JQ, Lapinski MW, Harold DJ, Myers JK: Focal nodular hyperplasia of the liver and intrahepatic hemorrhage in young women on oral contraceptives. Ann Intern Med 83:301–306, 1975
Mays ET, Christopherson WM, Barrows GH: Focal nodular hyperplasia of the liver. Am J Clin Pathol 61:735–746, 1974
Christopherson WM, Mays ET, Barrows GH: Liver tumors in women on contraceptive steroids. Obstet Gynecol 46:221–223, 1975
Ameriks JA, Thompson NW, Frey CF, Appelman HD, Walter JF: Hepatic cell adenomas, spontaneous liver rupture and oral contraceptives. Arch Surg 110:548–557, 1975
Baum JK, Hlotz F, Bookstein JJ, Klein EW: Possible association between benign hepatomas and oral contraceptives. Lancet 2:926–929, 1973
O'Sullivan JP, Wilding RP: Liver hematomas in patients on contraceptives. Br Med J 3:7–10, 1974
Porter LE, Elm MS, Van Thiel DH, Eagon PK: Hepatic estrogen receptor in human liver disease. Gastroenterology 92:735–745, 1987
Macdonald JS, Lippman ME, Wooley PV, Petrucci PP, Schein PS: Hepatic estrogen and progesteron receptors in an estrogen-associated hepatic neoplasm. Cancer Chemother Pharmacol 1:135–138, 1978
Mays ET, Christopherson W: Hepatic tumors induced by sex steroids. Sem Liver Dis 4:147–157, 1984
Demanes DJ, Friedman MA, McKerrow JH, Hoffman PG: Hormone receptors in hepatoblastoma: A demonstration of both estrogens and progesterone receptors. Cancer 50:1828–1832, 1982
Ohnishi S, Murakami T, Moriyama T, Mitamura K, Imawari M: Androgen and estrogen receptors in hepatocellular carcinoma and in the surrounding noncancerous liver tissue. Hepatology 6:440–443, 1986
Kohigashi K, Fukuda Y, Imura H: Estrogen receptors in hepatocellular carcinoma: Is endocrine therapy for hepatocellular carcinoma likely to be effective? Gastroenterol Jpn 22:322–330, 1987
Reznik-Schuller H: Carcinogenic effects of diethylstilbestrol in male Syrian Golden hamster and European hamster. J Natl Cancer Inst 62:1083–1088, 1979
Li JJ, Li SA: High incidence of hepatocellular carcinoma after synthetic estrogens administration in Syrian Golden hamster fed α-naphthoflavone: A new tumor model. J Natl Cancer Inst 73:543–547, 1984
Heston W, Vlahakis A, Desmukes B: Effect of the antifertility drug Enovid in five strains of mice, with particular regard to carcinogenesis. J Natl Cancer Inst 51:209–224, 1973
Toh YC: Physiologic and biochemical reviews of sex difference and carcinogenesis with particular reference to the liver. Adv Cancer Res 18:155–156, 1973
Yager JD, Yager R: Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats. Cancer Res 40:3680–3685, 1980
Sumi C, Yokoro K, Kajitani T, Ito A: Synergism of diethylstilbestrol and other carcinogens in concurrent development of hepatic, mammary, and pituitary tumors in castrated male rats. J Natl Cancer Inst 65:169–170, 1980
Schulte-Hermann R: Induction of liver growth by xenobiotic compounds and other stimuli. CRC Crit Rev Toxicol 3:97–98, 1979
Francavilla A, Di Leo A, Eagon PK, Wu SQ, Ove P, Van Thiel DH, Starzl TE: Regenerating rat liver: Correlation between estrogen receptor localization and deoxyribonucleic acid synthesis. Gastroenterology 86:562–567, 1984
Francavilla A, Polimeno L, Di Leo A, Barone M, Ove P, Coetzee M, Eagon P, Makowka L, Ambrosino G, Mazzaferro V, Starzl TE: The effect of tamoxifen on hepatocyte proliferationin vivo andin vitro. Hepatology 9:614–620, 1989
Okuda K, Peters RL, Simson WI: Gross anatomic features of hepatocellular carcinoma from three disparate geographic areas. Proposal of a new classification. Cancer 54:2165–2167, 1984
Melia WM, Johnson PJ, Williams R: Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 71(12):1213–1216, 1987
Guechot J, Peigney N, Ballet F, Vaubourdolle M, Giboudeau J, Poupon R: Sex hormone imbalance in male alcoholic cirrhotic patients with and without hepatocellular carcinoma. Cancer 62:760–762, 1988
Van Thiel DH, Lester R: The effect of chronic alcohol abuse on sexual function. Clin Endocrinol Metab 8:499–510, 1979
Eagon PK, Porter LE, Gavaler JS, Egler KM, Van Thiel DH: Effect of ethanol feeding upon levels of a male-specific hepatic estrogen binding protein: A possible mechanism for feminization. Alcoholism 5:183–187, 1981
Van Thiel DH, Gavaler JS: Ethanol and the endocrine system.In Alcohol-related Diseases in Gastoenterology. HK Seitz, B Kommerell (eds). Berlin, Springer-Verlag, 1985, pp 324–341
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Farinati, F., De Maria, N., Fornasiero, A. et al. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Digest Dis Sci 37, 659–662 (1992). https://doi.org/10.1007/BF01296419
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01296419